New CDMO, backed by private equity player, to manufacture biologics

17th October 2019 Uncategorised 0

Private equity player Ampersand Capital Partners, which this year sold Brammer Bio for $1.7 billion, is investing in another U.S. CDMO, this one targeted at sterile injectables.

More: New CDMO, backed by private equity player, to manufacture biologics
Source: fierce